| Literature DB >> 30013173 |
C Tur1, A Eshaghi2,3, D R Altmann2,4, T M Jenkins2, F Prados2,5, F Grussu2,3, T Charalambous2, A Schmidt6, S Ourselin5, J D Clayden7, C A M G Wheeler-Kingshott2,8,9, A J Thompson2,10, O Ciccarelli2,10, A T Toosy2.
Abstract
Brain structural covariance networks (SCNs) based on pairwise statistical associations of cortical thickness data across brain areas reflect underlying physical and functional connections between them. SCNs capture the complexity of human brain cortex structure and are disrupted in neurodegenerative conditions. However, the longitudinal assessment of SCN dynamics has not yet been explored, despite its potential to unveil mechanisms underlying neurodegeneration. Here, we evaluated the changes of SCNs over 12 months in patients with a first inflammatory-demyelinating attack of the Central Nervous System and assessed their clinical relevance by comparing SCN dynamics of patients with and without conversion to multiple sclerosis (MS) over one year. All subjects underwent clinical and brain MRI assessments over one year. Brain cortical thicknesses for each subject and time point were used to obtain group-level between-area correlation matrices from which nodal connectivity metrics were obtained. Robust bootstrap-based statistical approaches (allowing sampling with replacement) assessed the significance of longitudinal changes. Patients who converted to MS exhibited significantly greater network connectivity at baseline than non-converters (p = 0.02) and a subsequent connectivity loss over time (p = 0.001-0.02), not observed in non-converters' network. These findings suggest SCN analysis is sensitive to brain tissue changes in early MS, reflecting clinically relevant aspects of the condition. However, this is preliminary work, indicated by the low sample sizes, and its results and conclusions should be treated with caution and confirmed with larger cohorts.Entities:
Mesh:
Year: 2018 PMID: 30013173 PMCID: PMC6048099 DOI: 10.1038/s41598-018-29017-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographical, clinical and MRI characteristics of the study cohort.
| All HCs | All CIS | HCs vs. CIS, p-value | CIS-CISa | CIS-MSb | CIS-CISa vs. CIS-MSb, p-value | |
|---|---|---|---|---|---|---|
| N finally included | 7 | 21 | — | 12 | 9 | — |
| Age at study onset, mean (SD) | 30.143 | 32.238 | p = 0.405e | 30.917 | 34 | p = 0.268e |
| No. females | 5 | 18 | p = 0.393f | 10 | 8 | p = 0.719f |
| Cortical thickness at baseline, mean (SD) | 2.751 | 2.713 | p = 0.748g | 2.748 | 2.667 | p = 0.508g |
| Cortical thickness at 12 m, mean (SD) | 2.726 | 2.715 | p = 0.367g | 2.750 | 2.672 | p = 0.910g |
| Lesion volume at baseline, median (range) | — | 1.525 mL | — | 0.534 mL | 5.260 mL | p = 0.001e |
| Lesion volume at 3 months, median (range) | — | 1.828 mL | — | 0.631 mL | 6.113 mL | p = 0.001e |
| Lesion volume at 6 months, median (range) | — | 2.101 mL | — | 0.571 mL | 5.397 mL | p = 0.002e |
| Lesion volume at 12 months, median (range) | — | 2.918 mL | — | 0.756 mL | 5.322 mL | p = 0.005e |
| DISc at baseline, no. | — | 10 | — | 4 | 6 | p = 0.130f |
| DISc at 3 months, no. | — | 10 | — | 4 | 6 | p = 0.130f |
| DISc at 6 months, no. | — | 9 | — | 3 | 6 | p = 0.078f |
| DISc at 12 months, no. | — | 12 | — | 5 | 7 | p = 0.094f |
| DISc and DITc,d at baseline, no. | — | 0 | — | 0 | 0 | p > 0.99f |
| DISc and DITc,d at 3 months, no. | — | 3 | — | 0 | 3 | p = 0.031f |
| DISc and DITc,d at 6 months, no. | — | 6 | — | 2 | 4 | p = 0.202f |
| DISc and DITc,d at 12 months, no. | — | 9 | — | 3 | 6 | p = 0.058f |
aPatients who did not have a second attack during the follow-up; bpatients who had a second attack during the follow-up; caccording to the 2010 Revisions of the McDonald Criteria; dpatients did not undergo a whole-brain T1-weighted scan after Gadolinium injection. Therefore, it was not possible to assess whether gadolinium-enhancing lesions were coexisting with non-gadolinium-enhancing lesions, at any time point; etwo-sample t-test; fchi-square test; glinear regression adjusting for age, gender and T2 lesion load. Abbreviations: CIS: clinically isolated syndrome; DIS: dissemination in space; DIT: dissemination in time; HCs: healthy controls; SD: standard deviation.
Figure 1Network metrics over time in all CIS patients and HCs. This figure shows the evolution of network metrics over time for patients’ and controls’ networks, with the bootstrap standard errors. Although at follow-up only the mean shortest path was significantly different between patients’ and controls’ networks, at six-month follow-up, most of the metrics were significantly different between the two networks; *p < 0.05; **p < 0.01; ***p < 0.001.
One-year changes in SCN parameters, in CIS patients and HCs.
| CIS patients (all) | HCs | Patients vs. HCs, estimated p-value | |
|---|---|---|---|
|
| |||
|
| |||
| Change from baseline to 1 year | −3.62 (−12.29 to 2.19), p = 0.3 | −0.58 (−3.37 to 2.03), p = 0.7 | 0.50 |
|
| |||
| Change from baseline to 1 year | −0.06 (−0.19 to 0.02), p = 0.15 | −0.01 (−0.05 to 0.04), p = 0.8 | 0.30 |
|
| |||
|
| |||
| Change from baseline to 1 year | 0.36 (−0.13 to 0.89), p = 0.2 | 0.03 (−0.06 to 0.13), p = 0.6 | 0.25 |
|
| |||
| Change from baseline to 1 year | −0.05 (−0.14 to 0.02), p = 0.15 | −1.46 * 10−4 (−0.03 to 0.03), p = 0.99 | 0.20 |
|
| |||
| Change from baseline to 1 year | −0.06 (−0.17 to 0.01), p = 0.15 | −0.005 (−0.05 to 0.04), p = 0.9 | 0.25 |
|
| |||
|
| |||
| Change from baseline to 1 year | 0.02 (−0.01 to 0.06), p = 0.2 | 0.0054 (−0.03 to 0.04), p = 0.7 | 0.60 |
Comparison between CIS patients and HCs was made looking at the 95% CI. See main text for full details on the methods used. Significant p-values are indicated with bold letters. Abbreviations: CI: confidence interval; CIS: clinically isolated syndrome; FU: follow-up; HCs: healthy controls.
Figure 2Network metrics over time in MS converters and non-MS converters. This figure shows the evolution of network metrics over time for MS converters and non-MS converters, with the bootstrap standard errors. *p < 0.05; **p < 0.01; ***p < 0.001. Please look at Table 3 for more details.
One-year changes in SCN parameters, in CIS patients with and without clinical conversion to MS.
| Patients with clinical MS conversion | Patients without clinical MS conversion | Patients with vs. without clinical MS conversion, estimated p-value | |
|---|---|---|---|
|
| |||
|
| |||
| Change from baseline to 1 year | −10.18 (−16.22 to −0.87), | 2.39 (−1.03 to 7.52), p = 0.3 |
|
|
| |||
| Change from baseline to 1 year | −0.16 (−0.27 to −0.01), | 0.03 (−0.02 to 0.11), p = 0.4 |
|
|
| |||
|
| |||
| Change from baseline to 1 year | 0.56 (0.19 to 0.80), | −0.28 (−0.58 to −0.07), |
|
|
| |||
| Change from baseline to 1 year | −0.12 (−0.20 to −0.02), | 0.03 (−0.01 to 0.09), p = 0.2 |
|
|
| |||
| Change from baseline to 1 year | −0.15 (−0.25 to −0.01), | 0.03 (−0.02 to 0.10), p = 0.3 |
|
|
| |||
|
| |||
| Change from baseline to 1 year | 0.03 (−0.02 to 0.07), p = 0.5 | 0.01 (−0.02 to 0.03), p = 0.8 l | 0.5 |
Comparison between patients with and without MS conversion was made looking at the 95% CI. See main text for full details on the methods used. Significant p-values are indicated with bold letters. Abbreviations: CI: confidence interval; CIS: clinically isolated syndrome; FU: follow-up; HCs: healthy controls.
Figure 3Estimated monthly changes in nodal metrics for all groups. This figure shows the estimated monthly changes in the three node-level metrics: (A) nodal strength, (B) clustering coefficient and (C) local efficiency. In this figure, the size of the nodes indicates the absolute value of the change: bigger nodes have greater changes, in either direction, and smaller nodes have changes close to zero. Instead, the color of the nodes indicates the direction of the change: redder nodes indicate positive changes (increase) and bluer nodes indicate negative changes (decrease). The behavior over time of all-CIS network differed from that of HCs’ network, yet these differences did not reach statistical significance (see Table 2). This different behavior was mirrored by the two patient groups: whereas the non-converters’ network only showed minimal changes over time, the converters’ network showed an overall decrease in nodal strength, clustering coefficient and local efficiency. Of note, the regional distribution of nodes with greatest changes over time (pre- and post-central gyri and paracentral lobule, bilaterally) was similar for the all-CIS and the converters’ networks. Abbreviations: CIS: clinically isolated syndrome; HCs: healthy controls.
Summary table of the differences between groups.
| All CIS vs. HCs | CIS with vs. without MS conversion | CIS with MS conversion vs. HCs | CIS without MS conversion vs. HCs | |
|---|---|---|---|---|
|
| ||||
| Baseline | No |
| No | No |
| Change over time | No |
| No | No |
| Follow-up | No | No | No | No |
|
| ||||
| Baseline | No |
| No | No |
| Change over time | No |
| No | No |
| Follow-up | No | No | No | No |
|
| ||||
| Baseline | No |
| No |
|
| Change over time | No |
|
|
|
| Follow-up |
| No | No | No |
|
| ||||
| Baseline | No |
| No | No |
| Change over time | No |
|
| No |
| Follow-up | No | No | No | No |
|
| ||||
| Baseline | No |
| No | No |
| Change over time | No |
| No | No |
| Follow-up | No | No | No | No |
|
| ||||
| Baseline | No | No | No | No |
| Change over time | No | No | No | No |
| Follow-up | No | No | No | No |
This table indicates whether there were significant differences between groups (indicated as ‘Yes’) or not (indicated as ‘No’). Abbreviations: CIS: clinically isolated syndrome; HCs: healthy controls; MS: multiple sclerosis.
Figure 5Correlation matrices. This figure shows the correlation matrices for each one of the groups (all CIS, HCs, CIS with early conversion, CIS without early clinical conversion), at baseline and at follow-up. From these correlation matrices, we extracted the absolute values of the correlations and built the weighted graphs, used to obtain network metrics. Abbreviations: CIS: clinically isolated syndrome; HCs: healthy controls; MS: multiple sclerosis.
Figure 4Study pipeline. This is the study pipeline that we followed to obtain the network parameters at each time point and also the changes over 1 year. For each parameter and time point, and for each parameter change, 1000 bootstrap samples were used to compute the 95% Confidence Intervals. See main text for more details. Abbreviations: CIS: clinically isolated syndrome; HCs: healthy controls; FU: follow-up.